Premium
EFFECTS OF RESVERATROL ON TRIPLE NEGATIVE (ER‐, PR‐, HER2‐) BREAST CANCER CELLS
Author(s) -
Mangum Carla,
Cameron Joseph A.,
Herbert BrittneyShea
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.898.45
Subject(s) - resveratrol , triple negative breast cancer , breast cancer , estrogen receptor , cancer research , cancer , cancer cell , tamoxifen , medicine , cell growth , progesterone receptor , chemistry , pharmacology , biochemistry
Triple negative breast cancer is a subtype of cancer which lacks estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). There is no specific targeted therapy for triple negative breast cancers. Resveratrol, found in the skin of red grapes, is associated with a number of health benefits. Therefore, in order to investigate potential new treatment or chemopreventive options for triple negative breast cancer patients, we investigated the effects of resveratrol on triple negative cell lines. We show that resveratrol inhibits cell proliferation in a dose‐dependent fashion. Results also show that BRCA1 mutant cells are more sensitive to the resveratrol than the wild‐type BRCA1 cells, suggesting that BRCA1 may play a role. Non‐malignant breast cells were not as sensitive to resveratrol as the breast cancer cells lines. Our data also suggest that low concentrations of resveratrol (1–10 nM) may increase cell growth and telomerase activity. These studies provide insight into the dose dependent effects of resveratrol on breast cancer cells and the potential of resveratrol to be included in breast cancer treatment or chemoprevention regimens. NIGMS‐NIH Grant No. R25GM67592